Posted by Michael Wonder on 03 Jun 2020
CADTH publishes final recommendation for Crysvita
1 June 2020 - CADTH has completed its assessment of burosumab for the treatment of patients with X-linked hypophosphatemia.
CADTH's Canadian Drug Expert Committee has recommended that burosumab be reimbursed for the treatment of X-linked hypophosphatemia only if certain conditions are met.
One of the conditions is a price reduction.
